JP2006522747A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2006522747A5 JP2006522747A5 JP2006504354A JP2006504354A JP2006522747A5 JP 2006522747 A5 JP2006522747 A5 JP 2006522747A5 JP 2006504354 A JP2006504354 A JP 2006504354A JP 2006504354 A JP2006504354 A JP 2006504354A JP 2006522747 A5 JP2006522747 A5 JP 2006522747A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- aryl
- alkyloxy
- heteroaryl
- triazolo
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 125000000217 alkyl group Chemical group 0.000 claims 115
- 125000003118 aryl group Chemical group 0.000 claims 102
- 125000003545 alkoxy group Chemical group 0.000 claims 70
- 125000001072 heteroaryl group Chemical group 0.000 claims 48
- 150000001875 compounds Chemical class 0.000 claims 27
- 229910052739 hydrogen Inorganic materials 0.000 claims 24
- 239000001257 hydrogen Substances 0.000 claims 24
- 125000004104 aryloxy group Chemical group 0.000 claims 23
- 125000004122 cyclic group Chemical group 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 20
- 150000002431 hydrogen Chemical class 0.000 claims 19
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 19
- 229920006395 saturated elastomer Polymers 0.000 claims 19
- 125000005157 alkyl carboxy group Chemical group 0.000 claims 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 18
- 125000005843 halogen group Chemical group 0.000 claims 18
- 125000004432 carbon atom Chemical group C* 0.000 claims 16
- 239000000203 mixture Substances 0.000 claims 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 16
- 125000004043 oxo group Chemical group O=* 0.000 claims 14
- 238000004519 manufacturing process Methods 0.000 claims 13
- 229910052757 nitrogen Inorganic materials 0.000 claims 13
- 230000003287 optical effect Effects 0.000 claims 13
- 125000004953 trihalomethyl group Chemical group 0.000 claims 13
- 125000004951 trihalomethoxy group Chemical group 0.000 claims 12
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 12
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 claims 11
- 125000005129 aryl carbonyl group Chemical group 0.000 claims 11
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims 10
- 125000005842 heteroatom Chemical group 0.000 claims 10
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 10
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims 10
- 208000002705 Glucose Intolerance Diseases 0.000 claims 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 9
- 229910052799 carbon Inorganic materials 0.000 claims 9
- 150000001721 carbon Chemical group 0.000 claims 9
- 201000010099 disease Diseases 0.000 claims 9
- 208000035475 disorder Diseases 0.000 claims 9
- 229910052760 oxygen Inorganic materials 0.000 claims 9
- 239000001301 oxygen Chemical group 0.000 claims 9
- 201000009104 prediabetes syndrome Diseases 0.000 claims 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims 8
- 125000005553 heteroaryloxy group Chemical group 0.000 claims 8
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 8
- 230000002265 prevention Effects 0.000 claims 8
- 239000000126 substance Substances 0.000 claims 8
- 238000011282 treatment Methods 0.000 claims 8
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 7
- 150000003839 salts Chemical class 0.000 claims 7
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 6
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 6
- 229910052717 sulfur Chemical group 0.000 claims 6
- 239000011593 sulfur Chemical group 0.000 claims 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 4
- 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims 4
- 230000005764 inhibitory process Effects 0.000 claims 4
- 239000000651 prodrug Substances 0.000 claims 4
- 229940002612 prodrug Drugs 0.000 claims 4
- 125000006713 (C5-C10) cycloalkyl group Chemical group 0.000 claims 3
- JFUAWXPBHXKZGA-IBGZPJMESA-N 4-fluoro-2-[(4r)-5,5,5-trifluoro-4-hydroxy-2-methyl-4-(1h-pyrrolo[2,3-c]pyridin-2-ylmethyl)pentan-2-yl]phenol Chemical compound C([C@@](O)(CC=1NC2=CN=CC=C2C=1)C(F)(F)F)C(C)(C)C1=CC(F)=CC=C1O JFUAWXPBHXKZGA-IBGZPJMESA-N 0.000 claims 3
- 208000032928 Dyslipidaemia Diseases 0.000 claims 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 3
- 206010020772 Hypertension Diseases 0.000 claims 3
- 206010022489 Insulin Resistance Diseases 0.000 claims 3
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 3
- 208000008589 Obesity Diseases 0.000 claims 3
- 230000002159 abnormal effect Effects 0.000 claims 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims 3
- 125000002619 bicyclic group Chemical group 0.000 claims 3
- 239000008280 blood Substances 0.000 claims 3
- 210000004369 blood Anatomy 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 229940124750 glucocorticoid receptor agonist Drugs 0.000 claims 3
- 239000008103 glucose Substances 0.000 claims 3
- 230000003834 intracellular effect Effects 0.000 claims 3
- -1 methylenedioxo Chemical group 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 3
- 235000020824 obesity Nutrition 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- 150000000178 1,2,4-triazoles Chemical class 0.000 claims 2
- FVPNQJQFMJMQBP-UHFFFAOYSA-N 3-(2-bromophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound BrC1=CC=CC=C1C1=NN=C2N1CCCCC2 FVPNQJQFMJMQBP-UHFFFAOYSA-N 0.000 claims 2
- SKPQAQDIARRMKN-UHFFFAOYSA-N 3-phenyl-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound C1=CC=CC=C1C1=NN=C2N1C=CC1=CC=CC=C12 SKPQAQDIARRMKN-UHFFFAOYSA-N 0.000 claims 2
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 claims 2
- SGHVNADXQPDNSL-UHFFFAOYSA-N 5,5-dimethyl-3-thiophen-2-yl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=CS1 SGHVNADXQPDNSL-UHFFFAOYSA-N 0.000 claims 2
- 150000007513 acids Chemical class 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 210000005178 buccal mucosa Anatomy 0.000 claims 2
- 238000007911 parenteral administration Methods 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- 230000002685 pulmonary effect Effects 0.000 claims 2
- TVLMNUCPOGGEFL-UHFFFAOYSA-N 2-(6,6-dimethyl-7,8-dihydro-5H-[1,2,4]triazolo[4,3-a]pyrimidin-3-yl)phenol Chemical compound N12CC(C)(C)CNC2=NN=C1C1=CC=CC=C1O TVLMNUCPOGGEFL-UHFFFAOYSA-N 0.000 claims 1
- NJQBEFPUXBYGQT-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-5,5-dimethyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=C(Cl)C=C1Cl NJQBEFPUXBYGQT-UHFFFAOYSA-N 0.000 claims 1
- FTQFYENWBZENCJ-UHFFFAOYSA-N 3-(2,4-dichlorophenyl)-6,6-dimethyl-5,7-dihydro-1h-[1,2,4]triazolo[4,3-a]pyrimidine Chemical compound N12CC(C)(C)CNC2=NN=C1C1=CC=C(Cl)C=C1Cl FTQFYENWBZENCJ-UHFFFAOYSA-N 0.000 claims 1
- GWQHAEYSRALLID-UHFFFAOYSA-N 3-(2-chlorophenyl)-6,6-dimethyl-5,7-dihydro-1h-[1,2,4]triazolo[4,3-a]pyrimidine Chemical compound N12CC(C)(C)CNC2=NN=C1C1=CC=CC=C1Cl GWQHAEYSRALLID-UHFFFAOYSA-N 0.000 claims 1
- GKWMIVQJQWDXQZ-UHFFFAOYSA-N 3-(2-chlorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound ClC1=CC=CC=C1C1=NN=C2N1CCCCC2 GKWMIVQJQWDXQZ-UHFFFAOYSA-N 0.000 claims 1
- NVFDSULLRHMJQU-UHFFFAOYSA-N 3-(2-fluorophenyl)-5-(4-methoxyphenoxy)-[1,2,4]triazolo[4,3-c]quinazoline Chemical compound C1=CC(OC)=CC=C1OC(N12)=NC3=CC=CC=C3C2=NN=C1C1=CC=CC=C1F NVFDSULLRHMJQU-UHFFFAOYSA-N 0.000 claims 1
- AFRGNIDHOWKOTB-UHFFFAOYSA-N 3-(3,4-dichlorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=C(Cl)C(Cl)=CC=C1C1=NN=C2N1CCCCC2 AFRGNIDHOWKOTB-UHFFFAOYSA-N 0.000 claims 1
- NZYZRDCUROHPJS-UHFFFAOYSA-N 3-(3-bromophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound BrC1=CC=CC(C=2N3CCCCCC3=NN=2)=C1 NZYZRDCUROHPJS-UHFFFAOYSA-N 0.000 claims 1
- DYOWYUZNXBKQOK-UHFFFAOYSA-N 3-(3-chlorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound ClC1=CC=CC(C=2N3CCCCCC3=NN=2)=C1 DYOWYUZNXBKQOK-UHFFFAOYSA-N 0.000 claims 1
- AMYLUVBFQNSLRI-UHFFFAOYSA-N 3-(4-bromophenyl)-5,5-dimethyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=C(Br)C=C1 AMYLUVBFQNSLRI-UHFFFAOYSA-N 0.000 claims 1
- ADECVMMOLHCQTO-UHFFFAOYSA-N 3-(4-bromophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=CC(Br)=CC=C1C1=NN=C2N1CCCCC2 ADECVMMOLHCQTO-UHFFFAOYSA-N 0.000 claims 1
- PHGMTQJBXXFRJO-UHFFFAOYSA-N 3-(4-chlorophenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=CC(Cl)=CC=C1C1=NN=C2N1CCCCC2 PHGMTQJBXXFRJO-UHFFFAOYSA-N 0.000 claims 1
- LUGLLAHZGTUSAE-UHFFFAOYSA-N 3-(4-methoxyphenyl)-5,5,8,9-tetramethyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound C1=CC(OC)=CC=C1C1=NN=C2N1C(C)(C)CC1=CC(C)=C(C)C=C12 LUGLLAHZGTUSAE-UHFFFAOYSA-N 0.000 claims 1
- KXLBDDZCWXWYRL-UHFFFAOYSA-N 3-(4-methoxyphenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=CC(OC)=CC=C1C1=NN=C2N1CCCCC2 KXLBDDZCWXWYRL-UHFFFAOYSA-N 0.000 claims 1
- MDGGRHZKMXXZRD-UHFFFAOYSA-N 3-(4-methylphenyl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=CC(C)=CC=C1C1=NN=C2N1CCCCC2 MDGGRHZKMXXZRD-UHFFFAOYSA-N 0.000 claims 1
- OUNBBIYHRZELDA-UHFFFAOYSA-N 3-(5,5-dimethyl-6h-[1,2,4]triazolo[3,4-a]isoquinolin-3-yl)phenol Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=CC(O)=C1 OUNBBIYHRZELDA-UHFFFAOYSA-N 0.000 claims 1
- MMSKOIQDXOUXSX-UHFFFAOYSA-N 3-(5-bromopyridin-3-yl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound BrC1=CN=CC(C=2N3CCCCCC3=NN=2)=C1 MMSKOIQDXOUXSX-UHFFFAOYSA-N 0.000 claims 1
- UDKDUWDCNBRCHZ-UHFFFAOYSA-N 3-(5-hex-1-ynylpyridin-3-yl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound CCCCC#CC1=CN=CC(C=2N3CCCCCC3=NN=2)=C1 UDKDUWDCNBRCHZ-UHFFFAOYSA-N 0.000 claims 1
- VJQYEVURLUHRTB-UHFFFAOYSA-N 3-(6-chloropyridin-3-yl)-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound C1=NC(Cl)=CC=C1C1=NN=C2N1CCCCC2 VJQYEVURLUHRTB-UHFFFAOYSA-N 0.000 claims 1
- AGFZJQDWVBDHHF-UHFFFAOYSA-N 3-(furan-2-yl)-5,5,8,9-tetramethyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N=1N=C2C=3C=C(C)C(C)=CC=3CC(C)(C)N2C=1C1=CC=CO1 AGFZJQDWVBDHHF-UHFFFAOYSA-N 0.000 claims 1
- SQTDQYVVYDFZBN-UHFFFAOYSA-N 3-(furan-2-yl)-5,5-dimethyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=CO1 SQTDQYVVYDFZBN-UHFFFAOYSA-N 0.000 claims 1
- IWUWWHBHHKXIDC-UHFFFAOYSA-N 3-[2-(phenylmethoxymethyl)phenyl]-2,4,5-triazatricyclo[5.3.1.02,6]undeca-3,5-diene Chemical compound C=1C=CC=C(C=2N3C4CC(CCC4)C3=NN=2)C=1COCC1=CC=CC=C1 IWUWWHBHHKXIDC-UHFFFAOYSA-N 0.000 claims 1
- YNCFPURBKVPYQF-UHFFFAOYSA-N 3-phenyl-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound N12CCCCCC2=NN=C1C1=CC=CC=C1 YNCFPURBKVPYQF-UHFFFAOYSA-N 0.000 claims 1
- XCNFBPXYJPORHD-UHFFFAOYSA-N 3-pyridin-3-yl-6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepine Chemical compound N12CCCCCC2=NN=C1C1=CC=CN=C1 XCNFBPXYJPORHD-UHFFFAOYSA-N 0.000 claims 1
- RZQQPARKDTYYBY-UHFFFAOYSA-N 3-pyridin-4-yl-6,7,8,9-tetrahydro-5H-[1,2,4]triazolo[4,3-a]azepine Chemical compound N12CCCCCC2=NN=C1C1=CC=NC=C1 RZQQPARKDTYYBY-UHFFFAOYSA-N 0.000 claims 1
- QGMRICCOCAZISZ-UHFFFAOYSA-N 4-[5-(6,7,8,9-tetrahydro-5h-[1,2,4]triazolo[4,3-a]azepin-3-yl)pyridin-2-yl]morpholine Chemical compound C1COCCN1C1=CC=C(C=2N3CCCCCC3=NN=2)C=N1 QGMRICCOCAZISZ-UHFFFAOYSA-N 0.000 claims 1
- AUTMXVSOOABCRA-UHFFFAOYSA-N 4-benzyl-3,5-bis(4-methylphenyl)-1,2,4-triazole Chemical compound C1=CC(C)=CC=C1C(N1CC=2C=CC=CC=2)=NN=C1C1=CC=C(C)C=C1 AUTMXVSOOABCRA-UHFFFAOYSA-N 0.000 claims 1
- UMCSDNAWBPUNIJ-UHFFFAOYSA-N 5,5-dimethyl-3-(3,4,5-trimethoxyphenyl)-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound COC1=C(OC)C(OC)=CC(C=2N3C(C)(C)CC4=CC=CC=C4C3=NN=2)=C1 UMCSDNAWBPUNIJ-UHFFFAOYSA-N 0.000 claims 1
- LFESZQRDPUZMOE-UHFFFAOYSA-N 5,5-dimethyl-3-(4-methylphenyl)-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound C1=CC(C)=CC=C1C1=NN=C2N1C(C)(C)CC1=CC=CC=C12 LFESZQRDPUZMOE-UHFFFAOYSA-N 0.000 claims 1
- CSCOJYVCYSWDLT-UHFFFAOYSA-N 5,5-dimethyl-3-phenyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=CC=C1 CSCOJYVCYSWDLT-UHFFFAOYSA-N 0.000 claims 1
- IGGCFIIXILTKKF-UHFFFAOYSA-N 6,6-dimethyl-3-(2-nitrophenyl)-5,7-dihydro-1h-[1,2,4]triazolo[4,3-a]pyrimidine Chemical compound N12CC(C)(C)CNC2=NN=C1C1=CC=CC=C1[N+]([O-])=O IGGCFIIXILTKKF-UHFFFAOYSA-N 0.000 claims 1
- AHQPDKZRNZQLSQ-UHFFFAOYSA-N 7,10-dimethoxy-5,5-dimethyl-3-phenyl-6h-[1,2,4]triazolo[3,4-a]isoquinoline Chemical compound N12C(C)(C)CC=3C(OC)=CC=C(OC)C=3C2=NN=C1C1=CC=CC=C1 AHQPDKZRNZQLSQ-UHFFFAOYSA-N 0.000 claims 1
- 206010003210 Arteriosclerosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- SZTIGWGUVVLZIC-UHFFFAOYSA-N chembl1428630 Chemical compound N12C(C)(C)CC3=CC=CC=C3C2=NN=C1C1=CC=C(O)C=C1 SZTIGWGUVVLZIC-UHFFFAOYSA-N 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- QEXGSNIMFAVYDW-UHFFFAOYSA-N n-[(2-methoxyphenyl)methyl]-3-phenyl-[1,2,4]triazolo[4,3-b]pyridazin-6-amine Chemical compound COC1=CC=CC=C1CNC1=NN2C(C=3C=CC=CC=3)=NN=C2C=C1 QEXGSNIMFAVYDW-UHFFFAOYSA-N 0.000 claims 1
- 230000004770 neurodegeneration Effects 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200300571 | 2003-04-11 | ||
| US46728403P | 2003-05-02 | 2003-05-02 | |
| DKPA200300776 | 2003-05-22 | ||
| US47515703P | 2003-06-02 | 2003-06-02 | |
| PCT/DK2004/000251 WO2004089380A2 (en) | 2003-04-11 | 2004-04-06 | Pharmaceutical use of fused 1,2,4-triazoles |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2006522747A JP2006522747A (ja) | 2006-10-05 |
| JP2006522747A5 true JP2006522747A5 (https=) | 2007-05-31 |
Family
ID=33163033
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006504354A Pending JP2006522747A (ja) | 2003-04-11 | 2004-04-06 | 縮合１，２，４−トリアゾールの薬学的使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (3) | US7358238B2 (https=) |
| EP (1) | EP1615647B1 (https=) |
| JP (1) | JP2006522747A (https=) |
| AT (1) | ATE455547T1 (https=) |
| DE (1) | DE602004025220D1 (https=) |
| DK (1) | DK1615647T3 (https=) |
| ES (1) | ES2338656T3 (https=) |
| WO (1) | WO2004089380A2 (https=) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE602004025220D1 (de) * | 2003-04-11 | 2010-03-11 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen |
| US8460243B2 (en) | 2003-06-10 | 2013-06-11 | Abbott Diabetes Care Inc. | Glucose measuring module and insulin pump combination |
| US7722536B2 (en) | 2003-07-15 | 2010-05-25 | Abbott Diabetes Care Inc. | Glucose measuring device integrated into a holster for a personal area network device |
| US20100222316A1 (en) * | 2004-04-29 | 2010-09-02 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US8415354B2 (en) | 2004-04-29 | 2013-04-09 | Abbott Laboratories | Methods of use of inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7880001B2 (en) | 2004-04-29 | 2011-02-01 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme |
| CA3090413C (en) | 2004-06-04 | 2023-10-10 | Abbott Diabetes Care Inc. | Glucose monitoring and graphical representations in a data management system |
| US7838552B2 (en) | 2004-06-04 | 2010-11-23 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| US7803838B2 (en) * | 2004-06-04 | 2010-09-28 | Forest Laboratories Holdings Limited | Compositions comprising nebivolol |
| JP4882748B2 (ja) | 2004-09-16 | 2012-02-22 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| WO2006040329A1 (en) * | 2004-10-12 | 2006-04-20 | Novo Nordisk A/S | 1 ibeta- hydroxysteroid dehydrogenase type 1 active spiro compounds |
| US8198331B2 (en) | 2005-01-05 | 2012-06-12 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US20090192198A1 (en) | 2005-01-05 | 2009-07-30 | Abbott Laboratories | Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| JP5133702B2 (ja) | 2005-01-05 | 2013-01-30 | アボット・ラボラトリーズ | １１−β−ヒドロキシステロイドデヒドロゲナーゼ１型酵素の阻害薬 |
| WO2006074244A2 (en) | 2005-01-05 | 2006-07-13 | Abbott Laboratories | Adamantyl derivatives as inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme |
| US7579360B2 (en) | 2005-06-09 | 2009-08-25 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| US7572807B2 (en) | 2005-06-09 | 2009-08-11 | Bristol-Myers Squibb Company | Heteroaryl 11-beta-hydroxysteroid dehydrogenase type I inhibitors |
| MX2007016352A (es) | 2005-07-05 | 2008-03-05 | Hoffmann La Roche | Derivados de piridazina. |
| US7622492B2 (en) | 2005-08-31 | 2009-11-24 | Hoffmann-La Roche Inc. | Pyrazolones as inhibitors of 11β-hydroxysteroid dehydrogenase |
| BRPI0618051A2 (pt) * | 2005-11-01 | 2011-08-16 | Transtech Pharma Inc | uso farmacêutico de amidas substituìdas |
| KR20080076916A (ko) * | 2005-11-01 | 2008-08-20 | 트랜스테크 파르마, 인크. | 치환된 아미드의 약학적 사용 |
| EP1801098A1 (en) | 2005-12-16 | 2007-06-27 | Merck Sante | 2-Adamantylurea derivatives as selective 11B-HSD1 inhibitors |
| BRPI0708782A2 (pt) | 2006-03-16 | 2011-06-14 | Astellas Pharma Inc | derivado de triazol ou um sal deste |
| EP2007722A1 (en) * | 2006-03-21 | 2008-12-31 | High Point Pharmaceuticals, LLC | Adamantane derivatives for the treatment of the metabolic syndrome |
| KR20090014347A (ko) | 2006-04-07 | 2009-02-10 | 하이 포인트 파마슈티칼스, 엘엘씨 | 11β-히드록시스테로이드 탈수소효소 타입 1 활성 화합물 |
| PE20110235A1 (es) | 2006-05-04 | 2011-04-14 | Boehringer Ingelheim Int | Combinaciones farmaceuticas que comprenden linagliptina y metmorfina |
| EP2038255A2 (en) * | 2006-06-16 | 2009-03-25 | High Point Pharmaceuticals, LLC | Pharmaceutical use of substituted piperidine carboxamides |
| US8048908B2 (en) * | 2006-07-13 | 2011-11-01 | High Point Pharmaceuticals, Llc | 11β-hydroxysteroid dehydrogenase type 1 active compounds |
| EP1878721A1 (en) * | 2006-07-13 | 2008-01-16 | Novo Nordisk A/S | 4-Piperidylbenzamides as 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors |
| JP2010500300A (ja) | 2006-08-08 | 2010-01-07 | サノフィ−アベンティス | アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用 |
| KR20080052024A (ko) * | 2006-12-07 | 2008-06-11 | (주)아모레퍼시픽 | 아세틸-조효소 ａ 카복실라제 저해활성을 갖는트리아졸로피리다진 유도체 |
| DE102006058207A1 (de) * | 2006-12-11 | 2008-06-19 | Universitätsklinikum Schleswig-Holstein | Verfahren zur Herstellung spezifischer Inhibitoren der 11beta-Hydroxysteroid-Dehydrogenase Typ 1 mit Nor-Oleanan- oder Nor-Ursan-Grundgerüsten |
| EP1935420A1 (en) | 2006-12-21 | 2008-06-25 | Merck Sante | 2-Adamantyl-butyramide derivatives as selective 11beta-HSD1 inhibitors |
| EP2119719A1 (en) * | 2006-12-26 | 2009-11-18 | Daiichi Sankyo Company, Limited | Thiazepine derivative |
| EP2125704A1 (en) * | 2007-02-23 | 2009-12-02 | High Point Pharmaceuticals, LLC | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| ZA200904916B (en) | 2007-02-23 | 2010-09-29 | High Point Pharmaceuticals Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| JP2010519239A (ja) * | 2007-02-23 | 2010-06-03 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | １１−ベータ−ヒドロキシステロイドデヒドロゲナーゼの阻害因子としてのｎ−アドマンチルベンザミド |
| WO2008101907A2 (en) * | 2007-02-23 | 2008-08-28 | High Point Pharmaceuticals, Llc | N-adamantyl benzamides as inhibitors of 11-beta-hydroxysteroid dehydrogenase |
| CN101652359A (zh) * | 2007-03-09 | 2010-02-17 | 高点制药有限责任公司 | 作为羟类固醇脱氢酶抑制剂的吲哚-和苯并咪唑酰胺类 |
| EP2141990A4 (en) * | 2007-03-28 | 2011-07-06 | High Point Pharmaceuticals Llc | ACTIVE COMPOUNDS ON 11BETA-HSD1 |
| CN101677562A (zh) * | 2007-04-11 | 2010-03-24 | 高点制药有限责任公司 | 新化合物 |
| JP2010526777A (ja) * | 2007-04-24 | 2010-08-05 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | 置換アミドの医薬用途 |
| EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
| JP5736098B2 (ja) | 2007-08-21 | 2015-06-17 | アッヴィ・インコーポレイテッド | 中枢神経系障害を治療するための医薬組成物 |
| US8119658B2 (en) | 2007-10-01 | 2012-02-21 | Bristol-Myers Squibb Company | Triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors |
| WO2010001946A1 (ja) | 2008-07-03 | 2010-01-07 | アステラス製薬株式会社 | トリアゾール誘導体またはその塩 |
| WO2010003624A2 (en) | 2008-07-09 | 2010-01-14 | Sanofi-Aventis | Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof |
| JP2012509879A (ja) | 2008-11-21 | 2012-04-26 | ハイ ポイント ファーマシューティカルズ，リミティド ライアビリティ カンパニー | アダマンチルベンズアミド化合物 |
| WO2010068601A1 (en) | 2008-12-08 | 2010-06-17 | Sanofi-Aventis | A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof |
| FR2942797B1 (fr) * | 2009-03-03 | 2011-04-29 | Pf Medicament | Derives de benzothiazines, leur preparation et leur application a titre de medicaments |
| ES2350077B1 (es) | 2009-06-04 | 2011-11-04 | Laboratorios Salvat, S.A. | Compuestos inhibidores de 11beta-hidroxiesteroide deshidrogenasa de tipo 1. |
| MX2012001729A (es) | 2009-08-26 | 2012-06-13 | Sanofi Sa | Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo. |
| WO2011107494A1 (de) | 2010-03-03 | 2011-09-09 | Sanofi | Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| WO2011157827A1 (de) | 2010-06-18 | 2011-12-22 | Sanofi | Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| US8513430B2 (en) | 2010-07-27 | 2013-08-20 | High Point Pharmaceuticals, Llc | Substituted thiazol-2-ylamine derivatives, pharmaceutical compositions, and methods of use as 11-beta HSD1 modulators |
| US10136845B2 (en) | 2011-02-28 | 2018-11-27 | Abbott Diabetes Care Inc. | Devices, systems, and methods associated with analyte monitoring devices and devices incorporating the same |
| EP2683698B1 (de) | 2011-03-08 | 2017-10-04 | Sanofi | Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung |
| EP2683701B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| US8871758B2 (en) | 2011-03-08 | 2014-10-28 | Sanofi | Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof |
| WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
| EP2683702B1 (de) | 2011-03-08 | 2014-12-24 | Sanofi | Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
| US8895547B2 (en) | 2011-03-08 | 2014-11-25 | Sanofi | Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof |
| EP2683705B1 (de) | 2011-03-08 | 2015-04-22 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
| KR101332805B1 (ko) | 2011-03-31 | 2013-11-27 | 한국화학연구원 | 아다만틸기를 갖는 설파마이드 유도체 및 이의 약제학적으로 허용 가능한 염 |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| WO2013134562A1 (en) | 2012-03-09 | 2013-09-12 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| US8889730B2 (en) | 2012-04-10 | 2014-11-18 | Pfizer Inc. | Indole and indazole compounds that activate AMPK |
| AU2013363398B2 (en) | 2012-12-20 | 2017-06-01 | Tempest Therapeutics, Inc. | Triazolone compounds and uses thereof |
| CN105121439A (zh) | 2013-02-19 | 2015-12-02 | 辉瑞公司 | 作为pde4亚型抑制剂用于治疗cns和其他病症的氮杂苯并咪唑化合物 |
| JP6064062B2 (ja) | 2013-03-15 | 2017-01-18 | ファイザー・インク | Ａｍｐｋを活性化させるインダゾール化合物 |
| US9776976B2 (en) | 2013-09-06 | 2017-10-03 | Inception 2, Inc. | Triazolone compounds and uses thereof |
| CN103550217B (zh) * | 2013-10-31 | 2014-12-17 | 四川大学 | 一种靶向于细菌rna聚合酶的抗结核小分子化合物 |
| MX373103B (es) | 2014-02-13 | 2020-04-17 | Incyte Holdings Corp | Ciclopropilaminas como inhibidores de desmetilasa específica de lisina 1 (lsd1). |
| US9527835B2 (en) | 2014-02-13 | 2016-12-27 | Incyte Corporation | Cyclopropylamines as LSD1 inhibitors |
| SI3105218T1 (sl) | 2014-02-13 | 2019-11-29 | Incyte Corp | Ciklopropilamini kot inhibitorji LSD1 |
| EP3105219B9 (en) | 2014-02-13 | 2018-10-03 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| WO2016007722A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TWI687419B (zh) | 2014-07-10 | 2020-03-11 | 美商英塞特公司 | 作為ｌｓｄ１抑制劑之咪唑并吡啶及咪唑并吡嗪 |
| WO2016007727A1 (en) | 2014-07-10 | 2016-01-14 | Incyte Corporation | Triazolopyridines and triazolopyrazines as lsd1 inhibitors |
| TW201613925A (en) | 2014-07-10 | 2016-04-16 | Incyte Corp | Imidazopyrazines as LSD1 inhibitors |
| WO2016012896A1 (en) | 2014-07-24 | 2016-01-28 | Pfizer Inc. | Pyrazolopyrimidine compounds |
| PL3177624T3 (pl) | 2014-08-06 | 2019-09-30 | Pfizer Inc. | Związki imidazopirydazynowe |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| LT3334709T (lt) | 2015-08-12 | 2025-03-10 | Incyte Holdings Corporation | Lsd1 inhibitoriaus druskos |
| JP6999574B2 (ja) | 2016-04-22 | 2022-01-18 | インサイト・コーポレイション | Ｌｓｄ１阻害剤の製剤 |
| KR102919209B1 (ko) | 2018-08-10 | 2026-01-28 | 다이아핀 테라퓨틱스, 엘엘씨 | 트리-펩타이드 그리고 대사, 심장혈관 및 염증성 장애의 치료 |
| WO2020047198A1 (en) | 2018-08-31 | 2020-03-05 | Incyte Corporation | Salts of an lsd1 inhibitor and processes for preparing the same |
| CN113329754A (zh) | 2018-11-20 | 2021-08-31 | 麻雀制药股份有限公司 | 用于施用皮质类固醇的方法 |
| PL4116301T3 (pl) * | 2020-03-04 | 2026-02-16 | Japan Tobacco Inc. | Skondensowany związek tricykliczny i jego zastosowanie medyczne |
| EP4525983A4 (en) | 2022-05-16 | 2025-09-03 | Sparrow Pharmaceuticals Inc | METHODS AND COMPOSITIONS FOR TREATING GLUCOCORTICOID EXCESS |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US542105A (en) * | 1895-07-02 | Conduit electric railway | ||
| US825514A (en) * | 1905-11-16 | 1906-07-10 | James Bruce | Swab-holder. |
| DE1025881B (de) * | 1955-11-26 | 1958-03-13 | Bayer Ag | Verfahren zur Herstellung von Kondensationsprodukten |
| US2913454A (en) * | 1956-11-23 | 1959-11-17 | Schenley Ind Inc | Certain cycloalkanotriazoles, process and intermediates |
| ATE236164T1 (de) * | 1992-12-04 | 2003-04-15 | Janssen Pharmaceutica Nv | Antiallergische triazolobenzazepinderivate |
| US5426105A (en) * | 1993-09-24 | 1995-06-20 | G.D. Searle & Co. | Conformationally restricted angiotensin II antagonists |
| US5674879A (en) * | 1993-09-24 | 1997-10-07 | G.D. Searle & Co. | Compositions including and methods of using conformationally restricted angiotensin II antagonist |
| SE0001899D0 (sv) | 2000-05-22 | 2000-05-22 | Pharmacia & Upjohn Ab | New compounds |
| US6869666B2 (en) | 2001-05-02 | 2005-03-22 | 3M Innovative Properties Company | Controlled-puncture films |
| WO2002090092A1 (en) | 2001-05-04 | 2002-11-14 | Drebor Indústria De Artefatos De Borracha Ltda. | A device and a process for the retreading of tires |
| WO2002090093A1 (en) | 2001-05-04 | 2002-11-14 | Societe De Technologie Michelin | Improved autoclave for curing retreaded tires |
| WO2003065983A2 (en) * | 2002-02-01 | 2003-08-14 | Merck & Co., Inc. | 11-beta-hydroxysteroid dehydrogenase 1 inhibitors useful for the treatment of diabetes, obesity and dyslipidemia |
| US6756896B2 (en) * | 2002-04-11 | 2004-06-29 | Michael Brent Ford | Distributed residental alarm system and method therefor |
| DE602004025220D1 (de) * | 2003-04-11 | 2010-03-11 | High Point Pharmaceuticals Llc | Pharmazeutische verwendungen von kondensierten 1,2,4-triazolen |
-
2004
- 2004-04-06 DE DE602004025220T patent/DE602004025220D1/de not_active Expired - Lifetime
- 2004-04-06 AT AT04725884T patent/ATE455547T1/de not_active IP Right Cessation
- 2004-04-06 JP JP2006504354A patent/JP2006522747A/ja active Pending
- 2004-04-06 ES ES04725884T patent/ES2338656T3/es not_active Expired - Lifetime
- 2004-04-06 DK DK04725884.3T patent/DK1615647T3/da active
- 2004-04-06 EP EP04725884A patent/EP1615647B1/en not_active Expired - Lifetime
- 2004-04-06 WO PCT/DK2004/000251 patent/WO2004089380A2/en not_active Ceased
-
2005
- 2005-10-11 US US11/247,847 patent/US7358238B2/en not_active Expired - Fee Related
-
2008
- 2008-02-27 US US12/038,255 patent/US7723323B2/en not_active Expired - Fee Related
-
2010
- 2010-04-14 US US12/760,254 patent/US20100197658A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2006522747A5 (https=) | ||
| KR100887008B1 (ko) | 도파민 재수용 저해물질로 구성된 조성물 및 이를 이용하는방법 | |
| AU762128B2 (en) | Agents with an antidepressive effect | |
| JP2006522749A5 (https=) | ||
| CA2812034C (en) | Methods for concomitant treatment of theophylline and febuxostat | |
| JP2009515949A5 (https=) | ||
| US20130237526A1 (en) | Pharmaceutical composition | |
| KR20240136361A (ko) | 약학적 건조 분말 흡입 제제 | |
| JP2011520858A (ja) | 置換キナゾリン | |
| JP2022507533A (ja) | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 | |
| JPH10511080A (ja) | 哺乳類細胞の増殖を治療するためのハロゲン化芳香族の使用 | |
| JP2008538582A (ja) | 精神病性障害の治療または予防のための新規の治療的組み合わせ | |
| US8338442B2 (en) | Remedies for psychoneurosis | |
| MX2010012540A (es) | Derivados de imidazo[2,1-b]quinazolin-2-ona y su uso como agentes para inhibir la agregación plaquetaria. | |
| TW200838537A (en) | Substituted quinazolines | |
| US7132553B2 (en) | Product comprising an inhibitor of the transduction of heterotrimeric G protein signals combined with an anti-hypertensive agent for therapeutic use in the treatment of arterial hypertension | |
| CN1141590A (zh) | 用于预防和治疗凝血噁烷a2介导的疾病的药物 | |
| JP2002356445A (ja) | 多発性硬化症（ｍｓ）、他の脱髄症状ならびに末梢神経障害、特に有痛の神経障害および糖尿病性神経障害の多剤併用治療 | |
| US7338955B1 (en) | Medicament for treatment of neuropathies | |
| GB2609814A (en) | Terpenophenolic compounds and their use | |
| KR20010099648A (ko) | 신규 조성물 | |
| WO2000061144A1 (en) | Method and means for preventing, treating, and diagnosing cardiovascular complications in patients with obstructive sleep apnea | |
| US20230097253A1 (en) | Novel quinazoline compound as therapeutic agent for metabolic disorders | |
| CA2684171A1 (fr) | Utilisation du 4-cyclopropylmethoxy-n-(3,5-dichloro-1-oxydo-4-pyridin-4-yl)-5-(methoxy)pyridine-2-carboxamide pour le traitement des traumatismes craniens | |
| KR20010086459A (ko) | 코골이 및 해부학적 상부 기도의 높은 저항 증후군 치료용의약의 제조에서 ５ｈｔ２ａ 및 ５ｈｔ２ａ/ｃ 수용체길항제의 용도 |